Moreover, the results of a clinical pilot trial of exenatide suggested that treatment with this GLP1-R agonist for 12 months improved motor function in people with moderate Parkinson’s. GLP-1 receptor agonists are widely expressed in the central nervous system and drugs such as liraglutide, lixisenatide and exenatide have measurable brain concentrations, which makes them promising potential treatments for Parkinson’s.
Lixisenatide is a well-tolerated GLP-1R agonist that can be administered by injection once-daily. This clinical trial aims to assess the effects of lixisenatide, versus placebo, on both motor and non-motor symptoms in people with early stage Parkinson’s.
We are sorry that this content was not useful for you
Let us improve this content
Can you tell us how we can improve this content?